Highlights
The global Psoriasis Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Psoriasis is a genetic condition that may not be present at birth. The condition may be triggered by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, unhealthy diet, and sedentary living, which makes people more prone to this condition.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Psoriasis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psoriasis Drugs.
The Psoriasis Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Psoriasis Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psoriasis Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AbbVie
Amgen
Johnson & Johnson
Novartis
Eli Lilly & Company
AstraZeneca
Celgene Corporation
UCB
Merck
Segment by Type
Tumor Necrosis Factor Inhibitor
Interleukin Inhibitors
Others
Segment by Application
Topicals
Systemic
Biologics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psoriasis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psoriasis Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tumor Necrosis Factor Inhibitor
1.2.3 Interleukin Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Psoriasis Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Topicals
1.3.3 Systemic
1.3.4 Biologics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Psoriasis Drugs Market Perspective (2018-2029)
2.2 Psoriasis Drugs Growth Trends by Region
2.2.1 Global Psoriasis Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Psoriasis Drugs Historic Market Size by Region (2018-2023)
2.2.3 Psoriasis Drugs Forecasted Market Size by Region (2024-2029)
2.3 Psoriasis Drugs Market Dynamics
2.3.1 Psoriasis Drugs Industry Trends
2.3.2 Psoriasis Drugs Market Drivers
2.3.3 Psoriasis Drugs Market Challenges
2.3.4 Psoriasis Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psoriasis Drugs Players by Revenue
3.1.1 Global Top Psoriasis Drugs Players by Revenue (2018-2023)
3.1.2 Global Psoriasis Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Psoriasis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psoriasis Drugs Revenue
3.4 Global Psoriasis Drugs Market Concentration Ratio
3.4.1 Global Psoriasis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psoriasis Drugs Revenue in 2022
3.5 Psoriasis Drugs Key Players Head office and Area Served
3.6 Key Players Psoriasis Drugs Product Solution and Service
3.7 Date of Enter into Psoriasis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psoriasis Drugs Breakdown Data by Type
4.1 Global Psoriasis Drugs Historic Market Size by Type (2018-2023)
4.2 Global Psoriasis Drugs Forecasted Market Size by Type (2024-2029)
5 Psoriasis Drugs Breakdown Data by Application
5.1 Global Psoriasis Drugs Historic Market Size by Application (2018-2023)
5.2 Global Psoriasis Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Psoriasis Drugs Market Size (2018-2029)
6.2 North America Psoriasis Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Psoriasis Drugs Market Size by Country (2018-2023)
6.4 North America Psoriasis Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Psoriasis Drugs Market Size (2018-2029)
7.2 Europe Psoriasis Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Psoriasis Drugs Market Size by Country (2018-2023)
7.4 Europe Psoriasis Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psoriasis Drugs Market Size (2018-2029)
8.2 Asia-Pacific Psoriasis Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Psoriasis Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Psoriasis Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Psoriasis Drugs Market Size (2018-2029)
9.2 Latin America Psoriasis Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Psoriasis Drugs Market Size by Country (2018-2023)
9.4 Latin America Psoriasis Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psoriasis Drugs Market Size (2018-2029)
10.2 Middle East & Africa Psoriasis Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Psoriasis Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Psoriasis Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Psoriasis Drugs Introduction
11.1.4 AbbVie Revenue in Psoriasis Drugs Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Psoriasis Drugs Introduction
11.2.4 Amgen Revenue in Psoriasis Drugs Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Psoriasis Drugs Introduction
11.3.4 Johnson & Johnson Revenue in Psoriasis Drugs Business (2018-2023)
11.3.5 Johnson & Johnson Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Psoriasis Drugs Introduction
11.4.4 Novartis Revenue in Psoriasis Drugs Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 Eli Lilly & Company
11.5.1 Eli Lilly & Company Company Detail
11.5.2 Eli Lilly & Company Business Overview
11.5.3 Eli Lilly & Company Psoriasis Drugs Introduction
11.5.4 Eli Lilly & Company Revenue in Psoriasis Drugs Business (2018-2023)
11.5.5 Eli Lilly & Company Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Psoriasis Drugs Introduction
11.6.4 AstraZeneca Revenue in Psoriasis Drugs Business (2018-2023)
11.6.5 AstraZeneca Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Detail
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Psoriasis Drugs Introduction
11.7.4 Celgene Corporation Revenue in Psoriasis Drugs Business (2018-2023)
11.7.5 Celgene Corporation Recent Development
11.8 UCB
11.8.1 UCB Company Detail
11.8.2 UCB Business Overview
11.8.3 UCB Psoriasis Drugs Introduction
11.8.4 UCB Revenue in Psoriasis Drugs Business (2018-2023)
11.8.5 UCB Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Psoriasis Drugs Introduction
11.9.4 Merck Revenue in Psoriasis Drugs Business (2018-2023)
11.9.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AbbVie
Amgen
Johnson & Johnson
Novartis
Eli Lilly & Company
AstraZeneca
Celgene Corporation
UCB
Merck
*If Applicable.